We propose a therapeutic potential of focusing on endothelial dysfunction, vascular inflammation, and thrombosis, not just of ACE inhibitors but of other repurposed compounds that alone, or in combination with other drugs, might be used for protecting bypass grafts in COVID-19 infected CABG patients. This evidence concerns the gene ACE and COVID-19.